Cargando…
Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
The incidence and prevalence rate of chronic inflammatory disorders is on the rise in the pediatric population. Recent research indicates the crucial role of interactions between the altered intestinal microbiome and the immune system in the pathogenesis of several chronic inflammatory disorders in...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215716/ https://www.ncbi.nlm.nih.gov/pubmed/34163468 http://dx.doi.org/10.3389/fimmu.2021.642166 |
_version_ | 1783710295614554112 |
---|---|
author | Torun, Anna Hupalowska, Anna Trzonkowski, Piotr Kierkus, Jaroslaw Pyrzynska, Beata |
author_facet | Torun, Anna Hupalowska, Anna Trzonkowski, Piotr Kierkus, Jaroslaw Pyrzynska, Beata |
author_sort | Torun, Anna |
collection | PubMed |
description | The incidence and prevalence rate of chronic inflammatory disorders is on the rise in the pediatric population. Recent research indicates the crucial role of interactions between the altered intestinal microbiome and the immune system in the pathogenesis of several chronic inflammatory disorders in children, such as inflammatory bowel disease (IBD) and autoimmune diseases, such as type 1 diabetes mellitus (T1DM) and celiac disease (CeD). Here, we review recent knowledge concerning the pathogenic mechanisms underlying these disorders, and summarize the facts suggesting that the initiation and progression of IBD, T1DM, and CeD can be partially attributed to disturbances in the patterns of composition and abundance of the gut microbiota. The standard available therapies for chronic inflammatory disorders in children largely aim to treat symptoms. Although constant efforts are being made to maximize the quality of life for children in the long-term, sustained improvements are still difficult to achieve. Additional challenges are the changing physiology associated with growth and development of children, a population that is particularly susceptible to medication-related adverse effects. In this review, we explore new promising therapeutic approaches aimed at modulation of either gut microbiota or the activity of the immune system to induce a long-lasting remission of chronic inflammatory disorders. Recent preclinical studies and clinical trials have evaluated new approaches, for instance the adoptive transfer of immune cells, with genetically engineered regulatory T cells expressing antigen-specific chimeric antigen receptors. These approaches have revolutionized cancer treatments and have the potential for the protection of high-risk children from developing autoimmune diseases and effective management of inflammatory disorders. The review also focuses on the findings of studies that indicate that the responses to a variety of immunotherapies can be enhanced by strategic manipulation of gut microbiota, thus emphasizing on the importance of proper interaction between the gut microbiota and immune system for sustained health benefits and improvement of the quality of life of pediatric patients. |
format | Online Article Text |
id | pubmed-8215716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82157162021-06-22 Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children Torun, Anna Hupalowska, Anna Trzonkowski, Piotr Kierkus, Jaroslaw Pyrzynska, Beata Front Immunol Immunology The incidence and prevalence rate of chronic inflammatory disorders is on the rise in the pediatric population. Recent research indicates the crucial role of interactions between the altered intestinal microbiome and the immune system in the pathogenesis of several chronic inflammatory disorders in children, such as inflammatory bowel disease (IBD) and autoimmune diseases, such as type 1 diabetes mellitus (T1DM) and celiac disease (CeD). Here, we review recent knowledge concerning the pathogenic mechanisms underlying these disorders, and summarize the facts suggesting that the initiation and progression of IBD, T1DM, and CeD can be partially attributed to disturbances in the patterns of composition and abundance of the gut microbiota. The standard available therapies for chronic inflammatory disorders in children largely aim to treat symptoms. Although constant efforts are being made to maximize the quality of life for children in the long-term, sustained improvements are still difficult to achieve. Additional challenges are the changing physiology associated with growth and development of children, a population that is particularly susceptible to medication-related adverse effects. In this review, we explore new promising therapeutic approaches aimed at modulation of either gut microbiota or the activity of the immune system to induce a long-lasting remission of chronic inflammatory disorders. Recent preclinical studies and clinical trials have evaluated new approaches, for instance the adoptive transfer of immune cells, with genetically engineered regulatory T cells expressing antigen-specific chimeric antigen receptors. These approaches have revolutionized cancer treatments and have the potential for the protection of high-risk children from developing autoimmune diseases and effective management of inflammatory disorders. The review also focuses on the findings of studies that indicate that the responses to a variety of immunotherapies can be enhanced by strategic manipulation of gut microbiota, thus emphasizing on the importance of proper interaction between the gut microbiota and immune system for sustained health benefits and improvement of the quality of life of pediatric patients. Frontiers Media S.A. 2021-06-07 /pmc/articles/PMC8215716/ /pubmed/34163468 http://dx.doi.org/10.3389/fimmu.2021.642166 Text en Copyright © 2021 Torun, Hupalowska, Trzonkowski, Kierkus and Pyrzynska https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Torun, Anna Hupalowska, Anna Trzonkowski, Piotr Kierkus, Jaroslaw Pyrzynska, Beata Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children |
title | Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children |
title_full | Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children |
title_fullStr | Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children |
title_full_unstemmed | Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children |
title_short | Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children |
title_sort | intestinal microbiota in common chronic inflammatory disorders affecting children |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215716/ https://www.ncbi.nlm.nih.gov/pubmed/34163468 http://dx.doi.org/10.3389/fimmu.2021.642166 |
work_keys_str_mv | AT torunanna intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren AT hupalowskaanna intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren AT trzonkowskipiotr intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren AT kierkusjaroslaw intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren AT pyrzynskabeata intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren |